Search
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigationalcell types) that catalyze the synthesis of cyclic guanosine monophosphate (cGMP) in response to activation by nitric oxide (NO). … [L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure.
Piperonyl butoxide
go.drugbank.com/drugs/DB09350ApprovedVet approvedIt has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone.
Demeclocycline
go.drugbank.com/drugs/DB00618ApprovedA tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
Cyproheptadine
go.drugbank.com/drugs/DB00434ApprovedInvestigational[L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome.
Chymotrypsin
go.drugbank.com/drugs/DB09375ApprovedInvestigationalVet approvedWithdrawnChymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas [A32637]. … Chymotrypsin contains both the catalytic triad and oxyanion hole, and the tertiary structure of chymotrypsin is similar to [DB11237] [A32642].
Nalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawn[L40684] The nasal spray formulation of nalmefene was approved by the FDA in May 2023.[L46511] … It is used for complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
Vibrio cholerae CVD 103-HgR strain live antigen
go.drugbank.com/drugs/DB14443ApprovedInvestigational[L12801] Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. … [A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801]
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalOn May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … due to non-selective steroidal activities [A275513, A275514].
Synonyms: (+)-(r)-n-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide, N-((8r)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)propanamideRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigational[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] … Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA).
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigationalMarketed by Recordati Rare Diseases Inc., CYSTADROPS® reduce the burden of multiple frequent medications normally administered to those with cystinosis.[L15601] … [L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis.